Brought to you by 
Symetis gets CHF23mm through its Series B round
14 Jul 2009
Executive Summary
Symetis SA, which is developing the Acurate self-positioning device for percutaneous aortic valve replacement, has raised CHF23mm ($21.3mm) through its Series B venture round. Vinci Capital & Renaissance and Wellington Partners led the financing and were joined by fellow first-time investor Banexi Venture Partners and current shareholders Aravis Venture, BioMedInvest, Novartis Venture Funds, Truffle Capital, and individual backers. Symetis will use some of the funds to start in vivo preclinical testing of its Acurate TF transfemoral device.
Deal Industry
- Biotechnology
- Medical Devices
-
Medical Devices
- Biomaterials
- Implantable Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Symetis gets CHF23mm through its Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice